SOUTH AFRICA – MSD, a leading global biopharmaceutical company has appointed Dr Priya Agrawal as Managing Director for the South Africa and Sub-Saharan Africa Cluster.
The company in a press statement said that Dr Agrawal brings a wealth of public health experience with a strong track record for advancing successful public health initiatives within both the private and public sectors
The statement also revealed that Dr Agrawal trained as an Obstetrician and Gynaecologist in the United Kingdom.
After receiving her degrees in Medicine from the University of Cambridge and University of Oxford, she graduated with a master’s degree from the Harvard School of Public Health on a Fulbright Scholarship.
In her most recent role, Dr Agrawal was the Executive Director for Vaccines and Women’s Health in MSD’s UK subsidiary.
During this time, she built a high-performing team that helped to protect over 4 million people in the UK with MSD vaccines.
Dr Agrawal previously served as Executive Director of MSD for Mothers, a 10-year, US$500 million global initiative by MSD to create a world where no woman dies giving life.
She was critical in the successful launch of the project and led the global initiative for the company for four years.
Dr Agrawal, a fellow of the Royal Society of Medicine, has also worked and travelled in more than 45 countries where she has participated in the introduction of sustainable innovations to improve the health outcomes for underserved women and their families.
Immediately prior to joining MSD, she served as Director of Research and Innovation for the Women and Health Initiative at the Harvard School of Public Health where she led the development and evaluation of healthcare innovations.
In 2012, Dr Agrawal’s contributions to global health were recognized with the Harvard School of Public Health Alumni Award for Public Health Professionals and she was recently honoured with the Forbes Impact Award in Advocacy.
MSD is a leading global biopharmaceutical company that has been in operation for more than a century now.
The US based company mainly focuses on bringing forward medicines and vaccines for many of the world’s most challenging diseases.
The company which operates in more than 140 countries globally continues to be at the forefront of research to advance the prevention and treatment of life-threatening diseases including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.
